← Back to Search

Cancer Vaccine

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Phase 1
Waitlist Available
Research Sponsored by ModernaTX, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called mRNA-2736 for patients with a type of cancer that has come back or did not respond to other treatments. The drug is given through an IV to see how safe it is and how it affects the cancer.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: mRNA-2736Experimental Treatment1 Intervention
Participants will receive mRNA-2736.

Find a Location

Who is running the clinical trial?

ModernaTX, Inc.Lead Sponsor
121 Previous Clinical Trials
66,785,074 Total Patients Enrolled
1 Trials studying Multiple Myeloma
200 Patients Enrolled for Multiple Myeloma
~0 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top